Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEEPsAKE 1 risankizumab versus placebo in active psoriatic arthritis
NL-OMON55512Phase 3Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Jan 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in psoriatic arthritis (PsA) comparing Risankizumab with Placebo (2 arms). Primary endpoint: ACR20 response at Week 24. Started Jan 2020; status: active, not recruiting.
02
Drugs
risankizumab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NL-OMON55512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55512.